Daily Archives: September 6, 2018

New York City Real Estate Coin (NYCREC), A Tokenized Real Estate Fund With Cashflow Dividends, Announces Regulation S ICO in Q4 2018

Read about NYCREC at www.nycrec.io

NEW YORK, Sept. 06, 2018 (GLOBE NEWSWIRE) —  New York City Real Estate Coin (NYCREC), a tokenized real estate fund that allows token holders to enjoy the benefits of fractional ownership of real estate in New York City, has just announced that its Regulation S* securities token offering (STO) will begin in Q4 2018.

What is New York City Real Estate Coin?

NYCREC is the world’s first tokenized real estate fund focused on New York City real estate with an institutional-quality real estate and financial management team at the helm. It aims to give NYCREC token holders the following benefits:

  • Regular dividends from the cashflow of the properties in the NYCREC portfolio, distributed in the form of Ethereum (ETH) airdrops to token holders
  • Managed portfolio of real estate with greater flexibility and diversification than a similar real estate investment trust (REIT), which is typically narrower in its scope of investments
  • Lower expense fees than a similar real estate investment trust (REIT), leading to more pass-through profits for token holder
  • Independent financial reports on progress of the project and its finances after the ICO is completed
  • Increased accessibility to New York City real estate for the international community

The long-term vision of the project is to tokenize real estate in major gateway cities around the world and to build a dedicated, collateralized blockchain for asset-backed security token offerings.

The Team Behind New York City Real Estate Coin

The NYCREC has managed or invested over $15 billion in real estate projects in New York City and other major gateway cities worldwide over a 21-year career with a risk-adjusted, year-over-year internal rate of return of up to 25%.

The team is decorated with Wall Street investment professionals, including Chief Executive Officer Alain Oberrotman, former Worldwide Controller at McKinsey; Chief Blockchain Officer Neil Benedict, former Head of Product Development at BANKEX; Chief Operations Officer Paul Brownstein, who recently bought a $100mm NPL (Non-Performing Loan) portfolio; Charles Wyman, Chief Investment Officer and former Head of Global Credit Research at PIMCO; and Principal Steven Wasserman, Senior Advisor to a $4 billion NYC-based hedge fund. Advisors to the team include Leonard Seelig, Executive Director of BABB and Serg Gulko, CEO of XTRD.

To learn more about NYCREC, join the Telegram community (https://t.me/nycrec), follow them on Twitter @NYCRECoin, or email info@nycrec.io.

*NYCREC Tokens will only be offered by New York City Real Estate Coin to non-US persons in compliance with the registration provided by Regulation D and Regulation S of the United States Securities Exchange Act.

NYCREC is a tokenized real estate fund for New York City real estate with lower expense fees and greater diversification than a similar real estate investment trust (REIT). NYCREC Token holders will have the ability to receive dividends from the cashflow of the NYCREC portfolio in the form of Ethereum (ETH) airdrops. The team has managed or invested over $15 billion in real estate over their careers, with up to a 25% year-over-year risk-adjusted internal rate of return.

Steven Wasserman, Principal info@nycrec.io

Komet Reports Positive Results From Its 2018 Drill Program at Kabaya

QUÉBEC CITY, Sept. 06, 2018 (GLOBE NEWSWIRE) — Komet Resources Inc. (TSX-V: KMT) (“Komet” or the “Company”) is pleased to announce further encouraging results from a reverse circulation (RC) drill program that was completed this year on the Kabaya prospect in the southeastern part of the company’s Dabia South exploration property, located in western Mali, West Africa (Figures 1 and 2).

This RC drilling campaign extended the drill grid north and south of the Kabaya Main zone and completed the drill grid pattern over the Kabaya southwest zone (Figure 3). A total of 3,029 metres in 38, inclined and shallow step-out and infill drill holes (Km2018rc01-38) were realized to a vertical depth of around 65 m and defined gold mineralization with good grade continuity in the thick weathered rock profile (80 m of saprolite; Figure 3, 4 and 5). Gold mineralization systems were initially intercepted in both zones underneath a cluster of soil geochemistry anomalies in previous exploration drill campaigns (Robex Resources 2013–2014 and Komet Resources 2017; Figure 3).

Highlights of the drill results include 1.63 g/t over 17 m from 6 m; 1.06 g/t over 28 m from 30 m in Km2018RC12 and 1.60 g/t over 18 m from 8 m in Km2018rc15 in the Kabaya southeast zones, and 1.26 g/t over 33 m from 45 m in Km2018rc31, located in the northern part of the prospect, one of the last drill holes of the campaign and possibly indicating a new zone of economic gold mineralization.

Highlights From the Kabaya Program—Borehole Km2018rc01 to Km2018rc38:
HoleID Type From (m) To (m) Drill Width (m) Weighted Average Grade g/t Au
Km2018rc01 step-out 48 51 3 1.2
Km2018rc12 infil 6 23 17 1.6
Km2018rc12 30 58 28 1.1
Incl. 31 33 2 1.8
Incl. 47 50 3 2.0
Incl. 52 55 3 1.8
Km2018rc12 63 64 1 1.4
Km2018rc13 infil 12 20 8 1.1
Km2018rc13 24 31 7 1.2
Km2018rc13 33 41 8 1.1
Km2018rc15 infil 8 26 18 1.6
Km2018rc17 infil 59 61 2 1.1
Km2018rc19 infil 21 26 5 1.2
Km2018rc20 step-out 28 31 3 2.7
Km2018rc25 step-out 6 14 8 2.1
Incl. 7 11 4 3.8
Km2018rc26 step-out 21 28 7 1.5
Km2018rc31 step-out 17 19 2 1.1
Km2018rc31 45 78 33 1.3
Incl. 45 48 3 3.6
Incl. 50 53 3 1.9
Incl. 54 61 7 2.2
Km2018rc33 infil 68 76 8 2.7
Km2018rc34 infil 0 5 5 2.0
Km2018rc34 63 67 4 1.4
Km2018rc36 infil 60 64 4 1.5
Km2018rc36 68 70 2 2.0
Km2018rc36 76 79 3 1.8
Km2018rc37 step-out 10 20 10 1.2
Km2018rc38 step-out 41 45 4 1.9
*cut-off grade 0.5 g/t; no grade capping applied
** Widths are estimated 70 to 80% of true widths.

“The Kabaya Prospect RC drilling programs continue to provide excellent results and confirm substantial economic mineralization within the saprolite layer. Moreover, the significant gold intercept in hole Km2018RC31 reveals the probable existence of a new mineralized system in the northern part of the prospect. The Company will proceed with the Kabaya drill exploration program with the intention to grow economic resources as well laterally as in depth in bedrock. Furthermore, Komet as an explorer is well underway to provide an important contribution to the development of the Dabia Area as possible new world class gold district,” stated Werner Claessens, President and CEO of Komet.  

The 35 km² large Dabia South Exploration Permit is underlain by folded and sheared sequences of metasedimentary and metavolcanic facies, intruded by felsic and mafic plutons, which make part of the southeastern portion of the Paleoproterozoic Kedougou-Kenieba inlier, covering eastern Senegal and western Mali (figure 1). The property is located 15 km east of the north-south oriented regional Senegal-Mali Shear Zone (“SMSZ”). The SMSZ and its associated northeast-trending splay structures are spatially related to several major gold deposits such as Fekola, Loulo, Gounkoto and Sadiola.

Past exploration programs, carried out by other companies in the Dabia area, pointed out geochemical features and litho-structural settings which demonstrated the potential for the discovery of gold mineralization systems. In 1997 a soil sampling survey by Ashanti Mali SA revealed an interesting gold anomalous zone in the vicinity of the village Kabaya, located in the southeast portion of the Dabia permit. In the period 2013–2014 reconnaissance trenching and two small reverse circulation (RC) drilling campaigns, performed by Robex Resources Inc., identified economic gold mineralization. The results of a ground gravimetric survey, realized in 2014, suggest a shear zone controlled geological context. Kabaya gold occurrence could be associated with one of the splay structures of the regional shear structure SMSZ.

Komet continued the exploration drilling on the Kabaya exploration target in 2017 and 2018. Study of drill cuttings, artisanal gold pits and rejects and a few rare outcrops provide indications for a geological setting of quartz-vein stockwork and quartz veins/veinlets in strongly weathered meta sedimentary/volcano-sedimentary units.

All performed drilling (Komet Resources and Robex Resources) on the Kabaya prospect consisted of westward oriented inclined shallow holes (average drill depths of around 80 m), which identified economic mineralization mainly in the saprolite (weathered rock-) layer. Two mineralization zones appear, Kabaya main and Kabaya southwest, stretching at the surface over lengths of respectively 350 m and 150 m (figure 3). The gold mineralization remains open at depth in bedrock, underneath the saprolite layer, and laterally to the west of the Kabaya southwest zone (figures 3, 4 and 5). Hole Km2018rc31 intersected 33 m of economic mineralization in the northwest part of the Kabaya prospect and probably reveals a new resource zone.

A complete list of gold mineralized drill intercepts from boreholes Km2018rc01 to Km2018rc32 is provided as Exhibit 1 to this Press release.

Drilling supervision and sampling at the drill site were performed by Komet’s qualified technical staff, supervised by Jacques Marchand, P.Geo. Sample preparation, analytical testing and reporting of quantitative assays for the results reported in this press release were realized independently by the SGS Laboratory in Bamako, Mali. Fifty grams of pulverized material was analyzed for gold via Fire Assay with an atomic absorption spectroscopy (AAS) finish. A system of blanks, standards and duplicates were added to the sample stream to verify accuracy and precision of assay results, supplementing a variety of internal quality assurance/quality control (QA/QC) tests performed by SGS. The QA/QC program and the processing of results was designed by Pascal van Osta, P.Geo according to NI 43–101 regulation standards and best industry practices

The technical information in this document has been reviewed and approved by Pascal van Osta, P.Geo., Vice President Exploration, who has experience with the style of mineralization under consideration and is a Qualified Person under NI 43–101.

For more Information on Komet Resources inc.:

Lucas Werner Claessens
Chief Executive Officer
Email: lw.claessens@kometgold.com
Tel: +1-647-647-2285

Investors relations:
Carl Desjardins, Relations publiques Paradox inc.
Email: carldesjardins@paradox-pr.ca
Tel: +1-514-341-0408

About Komet Resources
Komet Resources Inc. is a Canadian-based gold mining and exploration company, listed on the TSX-V, with a focus on exploration and production at its projects in Burkina Faso and Mali, West Africa.

Qualified Person’s Review
Quality Assurance / Quality Control

The drill program and sampling protocol were managed by Komet under the supervision of Jacques Marchand, P.Geo. The reverse Circulation drill holes are drilled at 4-inch sizes. After the cyclone, the entire material corresponding to 1 m interval is collected and divided with a Jones Riffles splitter type to get a 2–3 kg sample. Analytical testing and reporting of quantitative assays for the Kabaya results reported in this press release was performed independently by SGS Mineral Mali SARLU accredited by SANAS and conforms to the requirements of ISO/IEC 17025:2005 for specific tests as indicated on the scope of accreditation to be found at http://sanas.co.za/. Gold analyses reported in this release was performed by standard fire assay (FA505) using a 50-gram charge with atomic absorption finish. A system of blanks, standards and duplicates were added by the Company to the sample streams to verify accuracy and precision of assay results, supplementing a variety of internal QA/QC tests performed by SGS Minerals. The samples were securely transported by Komet personnel from the project site to the SGS sample preparation facility in Bamako, Mali.

Forward-looking Statements
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains statements that may constitute “forward-looking information” or “forward-looking statements” as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet’s control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavourable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet’s management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

Exhibit 1
Gold mineralized drill intercepts from boreholes Km2018rc01 to Km2018rc38
Reverse Circulation Drill Program Spring 2018
HoleID Type From (m) To (m) Drill Width (m) Weighted Average Grade Au g/t
Km2018rc01 step-out 48 51 3 1.24
Km2018rc12 infil 6 23 17 1.63
Km2018rc12 30 58 28 1.06
Incl. 31 33 2 1.76
Incl. 47 50 3 2.01
Incl. 52 55 3 1.78
Km2018rc12 63 64 1 1.38
Km2018rc13 infil 12 20 8 1.07
Km2018rc13 24 31 7 1.21
Km2018rc13 33 41 8 1.11
Km2018rc13 44 59 15 0.81
Km2018rc13 63 68 5 0.80
Km2018rc14 infil 34 37 3 1.00
Km2018rc14 39 50 11 0.74
Km2018rc14 53 60 7 0.56
Km2018rc14 69 76 7 0.83
Km2018rc15 infil 8 26 18 1.60
Km2018rc15 39 55 16 0.94
Km2018rc16 infil 27 31 4 0.63
Km2018rc16 54 58 4 0.58
Km2018rc17 infil 28 31 3 0.95
Km2018rc17 59 61 2 1.06
Km2018rc17 74 80 6 0.77
Km2018rc18 infil 0 3 3 0.93
Km2018rc19 infil 21 26 5 1.20
Km2018rc19 66 68 2 0.94
Km2018rc20 step-out 28 31 3 2.65
Km2018rc20 51 53 2 0.58
Km2018rc25 step-out 6 14 8 2.11
Incl. 7 11 4 3.80
Km2018rc26 step-out 21 28 7 1.53
Km2018rc26 31 33 2 0.68
Km2018rc26 45 49 4 0.79
Km2018rc31 step-out 17 19 2 1.13
Km2018rc31 45 78 33 1.26
Incl. 45 48 3 3.59
Incl. 50 53 3 1.92
Incl. 54 61 7 2.24
Km2018rc33 infil 3 5 2 0.58
Km2018rc33 44 47 3 0.80
Km2018rc33 68 76 8 2.66
Km2018rc34 infil 0 5 5 2.03
Km2018rc34 10 14 4 0.71
Km2018rc34 24 25 1 0.66
Km2018rc34 39 46 7 0.54
Km2018rc34 51 57 6 0.84
Km2018rc34 63 67 4 1.35
Km2018rc36 infil 60 64 4 1.53
Km2018rc36 68 70 2 1.95
Km2018rc36 76 79 3 1.78
Km2018rc37 step-out 10 20 10 1.16
Km2018rc37 22 28 6 0.54
Km2018rc38 step-out 41 45 4 1.90
*cut-off grade 0.5 g/t; no grade capping applied
** Widths are estimated 70 to 80% of true widths.

Outstanding shares: 73,481,385

To view Figure 1, please click on the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/4edb1237-7f04-4fb0-8e86-f152dea593e5

To view Figure 2, please click on the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/6f5bc49b-6ecd-4f2c-8bbe-c20646dcb5e7

To view Figure 3, please click on the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/aa150ff1-8e03-4956-b929-3d8f0cd7dfe4

To view Figure 4, please click on the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/fd222506-e95e-4256-b9a6-0806bbdb438e

To view Figure 5, please click on the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/2f909ab7-8c1c-404d-82d2-58c552f9a6ae

PIMCO จ้างงาน John Studzinski ให้ดำรงตำแหน่งกรรมการผู้จัดการและรองประธาน PIMCO ในสำนักงานบริหารของบริษัท

  • Mr. Studzinski จะทำหน้าที่เป็นผู้นำในการขยายกลยุทธ์สากลของ PIMCO
  • Mr. Studzinski จะทำหน้าที่เป็นที่ปรึกษาหลักให้กับลูกค้าอันดับต้น ๆ ทั่วโลกของบริษัทร่วมกับทีมบริหารลูกค้าและผู้นำอาวุโส
  • Mr. Studzinski จะนำประสบการณ์ที่มีมากกว่า 30 ปีในฐานะเป็นที่ปรึกษาด้านการเงินที่ได้รับความไว้วางใจอย่างสูงที่ได้มอบให้กับผู้นำในธุรกิจ สถาบันการเงิน รัฐบาล และองค์กร NGO ต่าง ๆ ทั่วโลกมาสู่ PIMCO
  • เขาได้ทำงานในฐานะเป็นรองประธานบริษัท Blackstone Group รองประธานบริษัท Morgan Stanley International และทำงานในคณะกรรมการการจัดการกลุ่มของ HSBC
  • Mr. Studzinski ได้ทำงานอย่างไม่หยุดหย่อนในการสนับสนุนด้านเหตุแห่งมนุษยธรรมที่ช่วยปกป้องสิทธิและศักดิ์ศรีของผู้คนทั่วโลก

นิวพอร์ต บีช แคลิฟอร์เนีย, Sept. 06, 2018 (GLOBE NEWSWIRE) — PIMCO หนึ่งในผู้จัดการการลงทุนตราสารหนี้ที่สำคัญที่สุดในโลกได้เสนอให้ John Studzinski เข้าดำรงตำแหน่งเป็นกรรมการผู้จัดการและรองประธานบริษัทของ PIMCO ในสำนักงานผู้บริหาร Mr. Studzinski ผู้ที่ใช้เวลาในงานอาชีพของเขาทำงานในเอเชียและยุโรป นำประสบการณ์ที่มีมากกว่า 30 ปีในฐานะเป็นที่ปรึกษาด้านการเงินและกลยุทธ์ที่ได้รับความไว้วางใจ ผู้ที่ได้สร้างสัมพันธ์อันลึกซึ้งในบรรดาผู้นำของโลกในธุรกิจต่าง ๆ องค์กรการเงิน รัฐบาล และหน่วยงาน NGO มาสู่ PIMCO โดย Mr. Studzinski จะดำรงตำแหน่งที่สำนักงานของ PIMCO ที่นิวยอร์ค และจะรายงานต่อ Emmanuel Roman ซึ่งเป็นเจ้าหน้าที่บริหารสูงสุดของ PIMCO

สำหรับตำแหน่งใหม่นี้ของบริษัท Mr. Studzinski จะใช้ความรู้ความสามารถในระดับสากลอันกว้างขวาง รวมถึงเครือข่ายของเขา เพื่อสนับสนุนและเพื่อสร้างความก้าวหน้าให้กับกลยุทธ์ระดับสากลของ PIMCO รวมถึงทำงานเป็นที่ปรึกษาด้านกลยุทธ์ให้กับลูกค้าอันดับต้น ๆ ที่อยู่ทั่วโลกของ PIMCO ไม่ว่าจะเป็นกองทุนผู้เกษียณอายุภาคเอกชนและภาครัฐบาล บริษัทขนาดใหญ่ กองทุนความมั่งคั่งแห่งชาติ สำนักงานครอบครัวเดี่ยว รัฐบาล สมาคม และภาคส่วนอื่น ๆ อีกมากมาย Mr. Studzinski จะทำงานอย่างใกล้ชิดกับทีมบริหารลูกค้าของ PIMCO และผู้นำอาวุโสของบริษัท ไม่ว่าจะเป็น  Tom Otterbein หัวหน้าฝ่ายบริหารลูกค้าสถาบันในกลุ่มประเทศในทวีปอเมริกาของ PIMCO, Craig Dawson หัวหน้าของ PIMCO ในยุโรป ตะวันออกกลาง และแอฟริกา และ Kim Stafford หัวหน้าของ PIMCO ในเอเชีย-แปซิฟิก

Mr. Roman กล่าวว่า “ผมรู้จัก John เป็นการส่วนตัวและในงานอาชีพมาเป็นเวลา 20 ปี ผมมีความชื่นชมในประสบการณ์และความเชี่ยวชาญที่กว้างขวางอันน่าทึ่งของเขา รวมไปถึงความบูรณภาพ ภูมิความรู้ และความสัมพันธ์ของเขาด้วย เขาเป็นรัฐบุรุษของโลกการเงินอย่างแท้จริง การให้คำปรึกษาที่อยู่พื้นฐานข้อมูลเชิงลึกกับลูกค้าของเรานั้น เป็นหนึ่งในคุณค่าที่ยังคงอยู่ตลอดมาที่สำคัญที่สุดของ PIMCO มุมมองและประสบการณ์อันโดดเด่นและทรงพลังของ John ที่รวมกับผู้นำและทีมบริหารจัดการลูกค้าที่โดดเด่นของเรานั้น จะช่วยพิสูจน์ถึงคุณค่าที่ประเมินค่าไม่ได้ขณะที่เราขยายธุรกิจของเราไปทั่วโลก”

Mr. Studzinski กล่าวว่า “ผมมีความเคารพและความชื่นชมอย่างมากต่อความเฉียบแหลมของ PIMCO การมุ่งเน้นไปที่ลูกค้าอย่างมั่นคง และบทบาทที่สำคัญที่บริษัทมีเศรษฐกิจโลก ผมตื่นเต้นเกี่ยวกับการสร้างแรงผลักดันของ PIMCO ภายใต้การนำของ Manny และ Dan และยินดีอย่างยิ่งที่จะได้ร่วมในการสานต่อความสำเร็จและความก้าวหน้าของบริษัทต่อไป”

เกี่ยวกับ John Studzinski

ก่อนที่จะมาร่วมงานกับ PIMCO, Mr. Studzinski ได้ทำงานเป็นรองประธานบริษัท ฝ่ายลูกค้าสัมพันธ์สำหรับนักลงทุนและฝ่ายพัฒนาธุรกิจ และเป็นกรรมการผู้จัดการอาวุโสให้กับ Blackstone Group ได้ดูแลด้านความสัมพันธ์ผู้ลงทุนสถาบันและผู้ลงทุนสำหรับแห่งชาติ รวมถึงได้ให้คำปรึกษาด้านกลยุทธ์การลงทุนกับกลุ่มร่วมทุนของครอบครัวที่มีอิทธิพลและมีขนาดใหญ่ นอกจากนี้ เขายังได้ทำงานในฐานะเป็นหัวหน้าฝ่ายการธนาคารด้านการลงทุนในยุโรปที่ Morgan Stanley และเป็นรองประธานบริษัท Morgan Stanley International และเป็นผู้มีบทบาทสำคัญในแผนกพัฒนาการธนาคารเพื่อการลงทุนของ HSBC Group ที่ซึ่งเขาเป็นกรรมการการจัดการกลุ่มของธนาคาร

ยิ่งไปกว่านั้น ในงานด้านการเงินของ Mr. Studzinski เขายังได้ทำงานอย่างไม่หยุดหย่อนเพื่อช่วยเหลือเหตุแห่งมนุษยธรรมที่ช่วยปกป้องสิทธิและศักดิ์ศรีของทุกผู้คน ปัจจุบันเขาเป็นประธานขององค์กรริเริ่มธุรกิจการต่อต้านทาสสมัยใหม่ของนายกรัฐมนตรีของสหราชอาณาจักร เป็นผู้ก่อตั้งร่วมและประธานของมูลนิธิ Arise ซึ่งทำงานร่วมกับเครือข่ายท้องถิ่นทั่วโลกเพื่อหยุดยั้งการค้ามนุษย์ และเป็นรองประธาน Emeritus เพื่อการเฝ้าระวังด้านสิทธิมนุษยชน นอกจากนี้ เขายังเป็นผู้ก่อตั้งและเป็นประธานของมูลนิธิ Genesis ซึ่งเป็นมูลนิธิด้านการกุศลที่อยู่ในสหราชอาณาจักรที่ฝึกอบรมด้านอาชีพให้กับศิลปินเยาวชนที่มีความสามารถอันโดดเด่น

นอกจากนี้ Mr. Studzinski ยังได้รับเกียรติจากองค์สันตะปาปาในนามวีรบุรุษผู้บัญชาการคำสั่งของ St. Gregory และวีรบุรุษผู้บัญชาการของ St. Sylvester และได้รับขนานนามในปี 2008 ให้อยู่ในรายนามผู้ทรงเกียรติแห่งปีใหม่ของพระราชินีในฐานะเป็นผู้บัญชาการของจักรวรรดิบริติช (CBE) สำหรับงานที่สนองพระองค์ด้านศิลปะและการกุศล

เกี่ยวกับ PIMCO 

PIMCO เป็นหนึ่งในผู้จัดการการลงทุนตราสารหนี้ที่สำคัญที่สุดในโลก ด้วยการเปิดตัวบริษัทเมื่อปี พ.ศ. 1971 ในนิวพอร์ต บีช รัฐแคลิฟอร์เนีย PIMCO ได้นำผู้ลงทุนต่าง ๆ สู่เส้นทางการสร้างรายได้ตอบแทนรวมในการลงทุนกับตราสารหนี้ ในช่วงกว่า 45 ปีตั้งแต่นั้นมา เรานำนวัตกรรมและความเชี่ยวชาญมาสู่ความร่วมมือกับลูกค้าที่มองหาแนวทางการลงทุนที่ดีที่สุดของเราอย่างต่อเนื่อง ปัจจุบันเรามีสำนักงานอยู่ทั่วโลกและมีผู้เชี่ยวชาญมากกว่า 2,150 คนที่ร่วมในวัตถุประสงค์เดียวกัน นั่นคือ การสร้างโอกาสให้กับนักลงทุนในทุกสภาพการณ์ PIMCO อยู่ภายใต้การเป็นเจ้าของโดย Allianz S.E. ซึ่งเป็นผู้ให้บริการด้านการเงินที่หลากหลายทั่วโลก

เว้นแต่เป็นข้อมูลและการพูดคุยในอดีตที่ปรากฏอยู่ ณ ที่นี้ ข้อความที่ประกอบอยู่ในข่าวสารนี้ประกอบด้วยข้อความที่คาดการณ์ในอนาคต โดยมีความหมายภายใต้พระราชบัญญัติปฏิรูปการฟ้องร้องคดีหลักทรัพย์ส่วนบุคคลปี พ.ศ. 1995 ข้อความเหล่านี้อาจเกี่ยวเนื่องกับความเสี่ยง ความไม่แน่นอน และปัจจัยอื่น ๆ ที่อาจทำให้เกิดผลลัพธ์จริงที่แตกต่างจากผลลัพธ์ที่ระบุในเอกสารนี้ โดยรวมถึงการดำเนินการของตลาดการเงิน ประสิทธิภาพการลงทุนของผลิตภัณฑ์การลงทุนที่ได้รับการสนับสนุนและบัญชีจัดการแยกของ PIMCO สภาพทั่วไปทางเศรษฐกิจ การซื้อบริษัทในอนาคต สภาพการแข่งขัน และกฎระเบียบของรัฐบาล โดยรวมถึงการเปลี่ยนแปลงกฎหมายภาษี ผู้อ่านควรพิจารณาถึงปัจจัยเหล่านั้นอย่างรอบคอบ ยิ่งไปกว่านั้น ข้อความที่คาดการณ์ถึงอนาคตดังกล่าวจะอ้างถึงเฉพาะวันที่มีการจัดทำข้อความเท่านั้น PIMCO ไม่รับผิดชอบต่อหน้าที่การปรับปรุงข้อความที่คาดการณ์ถึงอนาคตใด ๆ ที่สะท้อนเหตุการณ์หรือสถานการณ์ภายหลังวันที่จัดทำข้อความดังกล่าว

Michael Reid
PIMCO – ฝ่ายสื่อ
โทร 212-597-1301

AbacusNext Document Automation Platform HotDocs Powers Legal Contract Drafting Service in China

 docQbot combines AI and HotDocs’ document assembly technology to help international companies do business with Chinese entities

SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) — HotDocs, an AbacusNext product and the global leader in document automation software, today announced its partnership with legal services provider, docQbot (Beijing docQbot Huiwen Data Technology Co., Ltd, a sister company of China Going Global Think-tank (“CGGT”)). HotDocs’ industry leading document automation technology will power docQbot’s recently launched bilingual contract drafting tool designed to aid organizations conducting international business with Chinese entities.

Currently in beta release, docQbot’s online contract service offers twenty fully automated, intelligent, contract templates. Each bilingual template can in many cases create hundreds of thousands or even millions of contract variations in both English and Chinese.  docQbot also is working with top law firms around the world to localize the base templates to support business transactions in more than 100 countries.

Templates available through the docQbot platform were designed by legal experts with a deep understanding of the Chinese market and the complexities associated with business negotiations. Gary Eunson, International Sales Director at AbacusNext, stated, “This docQbot solution is unique in that it combines artificial intelligence with HotDocs document automation technology to support the creation of multi-language documents in a very innovative way. This specialized consumer-facing application is the first of its kind and expands on the possibilities of what’s possible with document automation technology within the global marketplace. Businesses that tap into this contract generation tool will find that it simplifies so many of their challenges associated with complex international trade agreements.”

The contract generation tool is ideally suited for organizations conducting business with Chinese entities associated with outbound investments and foreign trade transactions. The easy-to-use interface makes it possible for legal professionals to quickly generate high-quality business contracts suited to early stage negotiations. Contracts can be created in as little as 10-15 minutes.

Mary Bai, co-founder and CEO of docQbot and CGGT, stated, “CGGT is very excited to team up with its sister company, docQbot, and with HotDocs to provide this unique legal AI solution to help both Chinese outbound investors and foreign trade companies avoid common problems and achieve more success in their cross-border deals. The docQbot tool makes it simple and easy to do contracts the right way. It is fast and low cost.”

docQbot also understands that most business contracts require additional expert counsel to address the unique aspects of each business arrangement. As such, docQbot can draw upon its close relationships with law firms in more than 100 countries to provide users with legal advice reaching beyond the scope of the docQbot tool. This allows Chinese and foreign trade companies to access in-country expertise needed to successfully conduct business internationally.

About HotDocs
HotDocs is the global industry leader in document automation technology, with customers in 60 countries and over one million users.  Document automation enables a vast reduction in time spent in the production of high volume, repeat documentation such as lending packages, credit documentation, and client on-boarding. Widely used within the banking, insurance, legal, government, and corporate sectors, HotDocs software helps to increase accuracy, reduce cost, eliminate risk, and improve efficiency in the generation of complex, or simple, repeat documentation.

For more information, visit www.hotdocs.com or connect with HotDocs on its blog, and on TwitterLinkedIn or Facebook.

About AbacusNext
As the largest Technology-as-a-Service (TaaS) provider for the professional services sector, AbacusNext helps legal and accounting professionals achieve ultimate success and peace of mind through the delivery of a complete suite of compliance-ready technology solutions designed to support a secure and cloud-enabled practice at a cost they can afford. Its portfolio of turnkey solutions includes hardware, software, and infrastructure on a pay-as-you-go model; Practice Management, Client Resource Management (CRM), Payment Processing, Email, Desktop-as-a-Service (DaaS), and Managed IT.

For more information, visit www.abacusnext.com or connect with AbacusNext on its blog, and on TwitterLinkedIn or Facebook.

About docQbot and CGGT
CGGT operates the China Going Global Think-tank platform, which provides Chinese enterprises with professional information and reports on outbound investment, covering strategy, finance, accounting, valuation, law, risk management, human resources, tax, and data and brand management. The docQbot solution is designed to help Chinese companies avoid common problems and achieve a greater level of success in both ODI and foreign trade transactions. All contracts are available in English and/or Chinese versions and are being localized for use in up to 100 countries and territories around the world. Just answer a few simple questions, and docQbot can produce a high-quality dual-language draft contract customized for your transaction in just a few minutes! Moreover, if you need offline support from qualified legal advisors, you will also be able to draw upon docQbot’s extensive network of leading lawyers across China and around the world. To learn more about docQbot and CGGT, visit www.cggthinktank.com and www.docqbot.com/en.


Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101

6 of 8 pts (75%) ORR in treatment-naïve EGFR mutation-positive NSCLC patients

Well-tolerated with unremarkable safety profile; No DLTs or related SAEs

Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019

NEW YORK, Sept. 06, 2018 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 (also known as RX518), a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being evaluated in advanced non-small cell lung cancer (NSCLC). The data will be presented on Monday, Sept. 24, at 10:30 a.m. ET in a late-breaking oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer in Toronto.

“These preliminary data demonstrate CK-101 is well-tolerated at the doses tested while also demonstrating encouraging anti-tumor activity, particularly in treatment-naïve EGFR mutation-positive lung cancer patients,” said Melissa L. Johnson, M.D., Associate Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology, PLLC, and study chair of the Phase 1/2 trial.

“The data to date demonstrate CK-101’s potential to be a highly effective mutant-selective EGFR inhibitor with the potential for a differentiated safety profile,” said James F. Oliviero, President and Chief Executive Officer of Checkpoint Therapeutics. “We look forward to continuing to advance CK-101 towards a pivotal Phase 3 trial next year, positioning CK-101 to potentially be only the second third-generation EGFR inhibitor to enter the market.”

The first-in-human, multicenter trial is evaluating CK-101 in NSCLC patients with EGFR mutations and other advanced malignancies (NCT02926768). Following dose escalation ranging from 100 mg to 1,200 mg/day in patients with any solid tumor where targeted EGFR was deemed reasonable, a first dose-expansion cohort was enrolled at 400 mg twice daily in patients with a confirmed diagnosis of either (1) EGFR mutation-positive advanced or metastatic NSCLC without prior exposure to EGFR-TKI therapy, or (2) T790M-positive advanced or metastatic NSCLC with disease progression on previous EGFR-TKI therapy. There was no limit on the number of prior lines of systemic therapy patients received prior to entering the study.

Key Data from the Abstract

As of June 2018, 37 patients had been treated with CK-101 in dose escalation and dose-expansion cohorts and were evaluable for safety.

  • No dose limiting toxicities (DLTs) or treatment-related serious adverse events (SAEs) were reported.
  • The most common drug-related treatment-emergent adverse events (>10%) included nausea (16%), diarrhea (14%), lacrimation increased (14%) and vomiting (11%).

In dose-expansion, 19 EGFR mutation-positive NSCLC patients were treated with CK-101 at a dose of 400 mg twice daily and were evaluable for response (RECIST v1.1). Eight patients achieved a partial response (7 confirmed, 1 pending).  Additional efficacy findings include:

  • In eight treatment-naïve patients, six patients (75%) achieved a partial response.
  • In six patients with brain metastases present at baseline, three patients achieved a partial response.
  • Higher drug exposures were associated with a higher response rate with a confirmed objective response rate (ORR) of 55% (6/11) in patients achieving a maximum serum concentration (Cmax) greater than 400 ng/mL.
  • 100% (19/19) disease control rate was observed, with 84% (16/19) of patients experiencing target lesion reduction versus baseline.
  • Median duration of response and progression-free survival were not reached as of the data cutoff.

Enrollment in the trial is ongoing to identify the optimal dose to maximize therapeutic effect.

Oral Presentation

Details of the oral presentation at the IASLC 19th World Conference on Lung Cancer are as follows:

Title: CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial
Date / Time: Monday, Sept. 24, 2018 at 10:30am
Session: Novel Therapies in ROS1, HER2 and EGFR
Presenter: Melissa L. Johnson, M.D., Associate Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tenn.

The full abstract can be found on the conference website and is also available on the Publications page in the Pipeline section of Checkpoint’s website, www.checkpointtx.com.

About CK-101

CK-101 (also known as RX518) is an oral, third-generation, irreversible kinase inhibitor against selective mutations in the EGFR gene. Activating mutations in the tyrosine kinase domain of EGFR, such as L858R and exon 19 deletion, are found in approximately 20 percent of patients with advanced non-small cell lung cancer (NSCLC).

Compared to chemotherapy, first-generation EGFR inhibitors significantly improved objective response rate and progression-free survival in previously untreated NSCLC patients carrying EGFR mutations. However, tumor progression could develop due to resistance mutations, often within months of treatment with first-generation EGFR inhibitors. The EGFR T790M “gatekeeper” mutation is the most common resistance mutation found in patients treated with first-generation EGFR inhibitors. The mutation decreases the affinity of first-generation inhibitors to EGFR kinase domain, rendering the drugs ineffective. Second-generation EGFR inhibitors have improved potency against the T790M mutation, but have not provided meaningful benefits in NSCLC patients due to toxicity from also inhibiting wild-type EGFR. Third-generation EGFR inhibitors are designed to be highly selective against both EGFR-TKI-sensitizing and resistance mutations, with minimal activity on wild-type EGFR, thereby improving tolerability and safety profiles.

Checkpoint Therapeutics is developing CK-101 for the treatment of NSCLC patients carrying the susceptible EGFR mutations. These include the EGFR T790M mutation in second-line NSCLC patients, as well as the EGFR L858R and exon 19 deletion mutations in first-line NSCLC patients.

Checkpoint holds an exclusive worldwide license (except with respect to certain Asian countries) to CK‐101, which it acquired from NeuPharma, Inc., in 2015.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, in a Phase 1/2 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In addition, Checkpoint is currently evaluating its lead antibody product candidate, CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in a Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers. Checkpoint plans to develop CK-301 as a treatment for patients with NSCLC and other solid tumors. Checkpoint, a Fortress Biotech company, is headquartered in New York City. For more information, visit www.checkpointtx.com.

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress”) (NASDAQ: FBIO) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensing arrangements, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com.

Forward‐Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to identify doses of CK-101 that increase drug exposure at safe levels; our ability to commence a Phase 3 trial for CK-101 in 2019; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500

Investor Relations Contact:
Jeremy Feffer
Managing Director, LifeSci Advisors, LLC
(212) 915-2568

Media Relations Contact:
Laura Bagby
6 Degrees
(312) 448-8098